Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase Ib data for NIS-793 plus spartalizumab in patients with advanced solid tumors

July 1, 2021

Updated phase I/II data for galinpepimut-S plus Keytruda in WT1-positive ovarian cancer

July 1, 2021

Atea presents interim phase II data for AT-527 in hospitalized patients with COVID-19

July 1, 2021

Retrotope initiates phase II study of RT-001 in progressive supranuclear palsy

July 1, 2021

Study suggests teicoplanin can improve outcomes in COVID pneumonia patients

July 1, 2021

Lilly describes first-in-human results with oxyntomodulin analogue LY-3305677

July 1, 2021

Tissue factor knockout human placenta adherent stromal cells tested in MS model

July 1, 2021

LG Chem patents sphingosine 1-phosphate receptor 1 agonists

July 1, 2021

Somatostatin SST5 receptor antagonists discovered at Kallyope

July 1, 2021

Janssen Pharmaceutica identifies new N-acetyl-beta-D-glucosaminidase inhibitors

July 1, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...